• Users Online: 105
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2021  |  Volume : 35  |  Issue : 3  |  Page : 140-144

Isobaric tags for relative and absolute quantitation in identifying proteins for clozapine treatment response in patients with schizophrenia: A preliminary study


1 Departments of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan
2 Department of Chemistry, National Sun Yat-Sen University, Kaohsiung, Taiwan
3 Departments of Psychiatry, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine; Department of Medical Research, Genomic and Proteomic Core Laboratory, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Correspondence Address:
Tiao- Lai Huang
123, Ta-Pei Road, Niao-Sung District, Kaohsiung 833
Taiwan
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/TPSY.TPSY_27_21

Rights and Permissions

Objective: Schizophrenia is a mental disorder characterized by reduced social engagement, abnormal emotional expression, and a lack of motivation. Isobaric tags for relative and absolute quantitation (iTRAQ) are a novel proteomic technique. In this study, we intended to identify potential biomarkers for predicting clozapine treatment response using iTRAQ. Methods: We identified patients with schizophrenia that responded to a four-week treatment with clozapine. Patient's peripheral blood mononuclear cells (PBMC) were collected before and after treatment. iTRAQ-based proteomics analysis was done to identify differentially expressed proteins in PBMC before and after treatment. STRING analysis map was built, and a target protein was selected. Western blot validation was then done. Results: In 10 identified clozapine treatment-responsive patients, we screened 2,735 proteins. Nine downregulated proteins and 11 upregulated proteins were differentially expressed by 1.5-fold after clozapine treatment. STRING network analysis revealed a series of apolipoproteins, and only apolipoprotein A4 (APOA-IV) was selected for validation. Western blot validations showed that protein levels of APOA-IV were significantly most downregulated in the patient after clozapine treatment (p = 0.05). Conclusion: In this study, we integrated clinical observation data, bioinformational protein interaction analysis, and iTRAQ labeling to study proteomics in patients with schizophrenia successfully treated with clozapine. We suggest that APOA-IV protein can be a biomarker for predicting clozapine treatment response in patients with schizophrenia. But these results in this study need a larger sample size to be validated.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed278    
    Printed0    
    Emailed0    
    PDF Downloaded49    
    Comments [Add]    

Recommend this journal